연구용
제품 번호S1342
| 세포주 | 분석 유형 | 농도 | 배양 시간 | 제형 | 활성 설명 | PMID |
|---|---|---|---|---|---|---|
| BxPC3 | Proliferation assay | Antiproliferative activity against human BxPC3 cell line by MTT assay, IC50=30 μM | 16789737 | |||
| BT20 | Proliferation assay | Antiproliferative activity against human BT20 cell line by MTT assay, IC50=46 μM | 16789737 | |||
| ANN-1 | Cytotoxic assay | Cytotoxic effect on v-abl transformed murine ANN-1 cells, IC50=8μM | 8201603 | |||
| breast carcinoma cells | Cytotoxic assay | Cytotoxic effect on MCF-7 human breast carcinoma cells, IC50=15.1μM | 8201603 | |||
| 3T3 | Cytotoxic assay | Cytotoxic effect on 3T3 cells, IC50=24μM | 8201603 | |||
| colon cells | Cytotoxic assay | Cytotoxic effect on WiDr human colon cells, IC50=27.7μM | 8201603 | |||
| Hepa1clc7 | Cytotoxicity assay | 72 hrs | Cytotoxicity against mouse Hepa1clc7 cells after 72 hrs, IC50=11μM | 10075742 | ||
| MCF7 | Function assay | 6 hrs | Inhibition of phorbol ester-induced ornithine decarboxylase in human MCF7 cells after 6 hrs, IC50=26μM | 10075742 | ||
| 3T3/A31 | Cytotoxicity assay | 1 to 100 ug/mL | 72 hrs | Cytotoxicity against BALB/c mouse cloned 3T3/A31 cells at 1 to 100 ug/mL after 72 hrs by nigrosin assay | 10096863 | |
| SH-SY5Y | Function assay | Agonist activity in transcriptional activation assay in SH-SY5Y neuroblastoma cells expressing Estrogen receptor beta, EC50=0.0017μM | 11906280 | |||
| HeLa | Function assay | Activation of estrogen response element in HeLa cells stably transfected with human Estrogen receptor beta., EC50=0.0041μM | 11906280 | |||
| HeLa | Function assay | Activation of estrogen response element in HeLa cells stably transfected with human Estrogen receptor alpha., EC50=0.048μM | 11906280 | |||
| Ishikawa | Estrogenic assay | 4 days | Estrogenic activity in human Ishikawa cells assessed as induction of alkaline phosphatase activity after 4 days by para-nitrophenol release assay, IC50=0.51μM | 12502307 | ||
| Hepa-1c1c7 | Function assay | Induction of NADPH:quinone reductase in mouse Hepa-1c1c7 cells assessed as drug level required to double enzyme activity by MTT assay, CD=22.9μM | 14510590 | |||
| Hepa-1c1c7 | Function assay | Inhibition of mouse Hepa-1c1c7 cells by MTT assay, IC50=45.2μM | 14510590 | |||
| T47D | Estrogenic assay | Estrogenic activity in human T47D cells assessed as drug level causing stimulation of cell proliferation equivalent to 10 pM estradiol by alamar blue assay, Activity=0.001μM | 15787436 | |||
| MCF7 | Estrogenic assay | Estrogenic activity in human MCF7 cells assessed as drug level causing stimulation of cell proliferation equivalent to 10 pM estradiol by alamar blue assay, Activity=0.003μM | 15787436 | |||
| T47D | Estrogenic assay | Estrogenic activity in human T47D cells assessed as drug level causing stimulation of cell proliferation equivalent to 100 pM estradiol by alamar blue assay, Activity=0.009μM | 15787436 | |||
| MCF7 | Estrogenic assay | Estrogenic activity in human MCF7 cells assessed as drug level causing stimulation of cell proliferation equivalent to 100 pM estradiol by alamar blue assay, Activity=0.013μM | 15787436 | |||
| 293T | Function assay | Displacement of [3H]17beta-estradiol from recombinant human ERbeta expressed in 293T cells, IC50=0.0013μM | 16219463 | |||
| 293T | Function assay | Displacement of [3H]17beta-estradiol from recombinant human ERalpha expressed in 293T cells, IC50=0.0294μM | 16219463 | |||
| Vero | Cytotoxicity assay | Cytotoxicity against african green monkey Vero cells, IC50=32.9μM | 16441066 | |||
| U937 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay, IC50=48μM | 17158054 | ||
| RAW 264 | Function assay | 24 hrs | Inhibition of 1 ug/ml LPS-stimulated TNFalpha accumulation in RAW 264 cells after 24 hrs, IC50=18.1μM | 17320246 | ||
| K562 | Growth inhibition assay | 5 days | Growth inhibition of K562 cells by XTT assay after 5 days, IC50=17.56μM | 17411092 | ||
| HUVE12 | Function assay | Reversal of hydrogen peroxide-induced LDH activity in human HUVE12 cells | 18068980 | |||
| HL60 | Antileukemic assay | 24 hrs | Antileukemic activity against human HL60 cells after 24 hrs by clonogenic assay, LC50=6.3μM | 18163589 | ||
| L1210 | Antileukemic assay | 24 hrs | Antileukemic activity against mouse L1210 cells after 24 hrs by clonogenic assay, LC50=6.5μM | 18163589 | ||
| MOLT3 | Antileukemic assay | 24 hrs | Antileukemic activity against human MOLT3 cells after 24 hrs by clonogenic assay, LC50=7.5μM | 18163589 | ||
| MOLT3 | Growth inhibition assay | 48 hrs | Growth inhibition of human MOLT3 cells after 48 hrs, IG50=12.7μM | 18163589 | ||
| Raji | Antileukemic assay | 24 hrs | Antileukemic activity against human Raji cells after 24 hrs by clonogenic assay, LC50=13.7μM | 18163589 | ||
| HL60 | Growth inhibition assay | 48 hrs | Growth inhibition of human HL60 cells after 48 hrs, IG50=18.2μM | 18163589 | ||
| L1210 | Growth inhibition assay | 24 hrs | Growth inhibition of mouse L1210 cells after 24 hrs, IG50=18.5μM | 18163589 | ||
| Raji | Growth inhibition assay | 48 hrs | Growth inhibition of human Raji cells after 48 hrs, IG50=18.6μM | 18163589 | ||
| KG1a | Growth inhibition assay | 48 hrs | Growth inhibition of human KG1a cells after 48 hrs, IG50=23μM | 18163589 | ||
| L1210 | Function assay | 1 to 20 uM | 24 hrs | Induction of p15CDKN2B re-expression in mouse L1210 cells at 1 to 20 uM after 24 hrs by RT-PCR | 18163589 | |
| HEK293 | Function assay | Antagonist activity at human recombinant LXRbeta expressed in HEK293 cells by luciferase reporter gene assay, IC50=22μM | 18343126 | |||
| HEK293 | Function assay | Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay, IC50=31μM | 18343126 | |||
| NIH3T3 | Function assay | Agonist activity at CFTR-deltaF508 mutant expressed in NIH3T3 cells assessed as increase in forskolin-stimulated current, EC50=4.4μM | 18595696 | |||
| NHEM | Function assay | 72 hrs | Inhibition of melanin synthesis in NHEM cells assessed as [14C]thiouracil incorporation after 72 hrs by liquid scintillation counting, IC50=29.2μM | 19132934 | ||
| RAW264.7 | Function assay | Inhibition of LPS-induced TNFalpha release in mouse RAW264.7 cells pretreated 1 hr before LPS challenge by enzyme immunoassay, IC50=26.5μM | 19278854 | |||
| MDA-kb2 | Function assay | Agonist activity at androgen receptor in human MDA-kb2 cells assessed as stimulation of luciferase activity by luciferase reporter gene assay, EC150=4.4μM | 19592245 | |||
| MDA-kb2 | Function assay | Agonist activity at glucocorticoid receptor in human MDA-kb2 cells assessed as stimulation of luciferase activity by luciferase reporter gene assay, EC150=4.4μM | 19592245 | |||
| MCF7 | Antiproliferative assay | Antiproliferative activity against estrogen receptor expressing human MCF7 cells, GI50=10μM | 19818612 | |||
| MDA-MB-436 | Antiproliferative assay | Antiproliferative activity against estrogen receptor expressing human MDA-MB-436 cells, GI50=17μM | 19818612 | |||
| FRT | Function assay | Binding affinity to CFTR deltaF508 mutant expressed in FRT cells coexpressing halide sensitive YFP-H148Q/I152L mutant protein by iodide influx assay, Kd=16.7μM | 19880323 | |||
| T47D | Estrogenic assay | 96 hrs | Estrogenic activity in human T47D cells assessed as drug level causing stimulation of cell proliferation equivalent to 10 pM estradiol after 96 hrs by alamar blue assay, Activity=0.01μM | 19928832 | ||
| MCF7 | Estrogenic assay | 96 hrs | Estrogenic activity in human MCF7 cells assessed as drug level causing stimulation of cell proliferation equivalent to 10 pM estradiol after 96 hrs by alamar blue assay, Activity=0.01μM | 19928832 | ||
| MCF7 | Estrogenic assay | Estrogenic activity in luciferase transfected human MCF7 cells assessed as drug level causing stimulation of cell proliferation equivalent to 10 pM estradiol by luciferase reporter gene assay, Activity=0.01μM | 19928832 | |||
| MCF7 | Estrogenic assay | Estrogenic activity in luciferase transfected human MCF7 cells assessed as drug level causing stimulation of cell proliferation equivalent to 100 pM estradiol by luciferase reporter gene assay, Activity=0.01μM | 19928832 | |||
| T47D | Estrogenic assay | Estrogenic activity in luciferase transfected human T47D cells assessed as drug level causing stimulation of cell proliferation equivalent to 10 pM estradiol by luciferase reporter gene assay, Activity=0.01μM | 19928832 | |||
| T47D | Estrogenic assay | 96 hrs | Estrogenic activity in human T47D cells assessed as drug level causing stimulation of cell proliferation equivalent to 100 pM estradiol after 96 hrs by alamar blue assay, Activity=0.08μM | 19928832 | ||
| MCF7 | Estrogenic assay | 96 hrs | Estrogenic activity in human MCF7 cells assessed as drug level causing stimulation of cell proliferation equivalent to 100 pM estradiol after 96 hrs by alamar blue assay, Activity=0.11μM | 19928832 | ||
| T47D | Estrogenic assay | Estrogenic activity in luciferase transfected human T47D cells assessed as drug level causing stimulation of cell proliferation equivalent to 100 pM estradiol by luciferase reporter gene assay, Activity=0.6μM | 19928832 | |||
| RAW264.7 | Antiinflammatory assay | 24 hrs | Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production after 24 hrs by Griess reagent, IC50=26μM | 20363145 | ||
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay, IC50=1μM | 20813524 | ||
| LoVo | Cytotoxicity assay | 72 hrs | Cytotoxicity against human LoVo cells after 72 hrs by MTT assay, IC50=15.88μM | 21129977 | ||
| LNCAP | Cytotoxicity assay | 72 hrs | Cytotoxicity against human LNCAP cells after 72 hrs by SRB assay, IC50=30.65μM | 21129977 | ||
| HCT116 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay, IC50=34.9μM | 21129977 | ||
| AGS | Cytotoxicity assay | 72 hrs | Cytotoxicity against human AGS cells after 72 hrs by MTT assay, IC50=41.67μM | 21129977 | ||
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A549 cells after 72 hrs by SRB assay, IC50=43.09μM | 21129977 | ||
| DU145 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human DU145 cells after 72 hrs by MTT assay, IC50=47.29μM | 21129977 | ||
| RAW264.7 | Antiinflammatory assay | 24 hrs | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production treated 2 hrs before LPS challenge measured after 24 hrs by ELISA, IC50=19.1μM | 21288727 | ||
| MDCK | Function assay | Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining, IC50=6.9μM | 21354800 | |||
| MCF-7 MX | Function assay | Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining, IC50=8.8μM | 21354800 | |||
| NCI-ADR-RES | Antiproliferative assay | 48 hrs | Antiproliferative activity against estrogen receptor-deficient human NCI-ADR-RES cells incubated with 0.06 nM of estradiol and 0.07 nM of testosterone after 48 hrs by sulforhodamine B assay in presence of fetal bovine serum and NuSerum, GI50=16.9824μM | 21513275 | ||
| MCF12A | Antiproliferative assay | 48 hrs | Antiproliferative activity against estrogen receptor-deficient human MCF12A cells incubated with 0.06 nM of estradiol and 0.07 nM of testosterone after 48 hrs by sulforhodamine B assay in presence of fetal bovine serum and NuSerum, GI50=21.8776μM | 21513275 | ||
| NCI-ADR-RES | Antiproliferative assay | 48 hrs | Antiproliferative activity against estrogen receptor-deficient human NCI-ADR-RES cells incubated with 100 nM of estradiol and 0.07 nM of testosterone after 48 hrs by sulforhodamine B assay in presence of fetal bovine serum and NuSerum, GI50=26.9154μM | 21513275 | ||
| MCF12A | Antiproliferative assay | 48 hrs | Antiproliferative activity against estrogen receptor-deficient human MCF12A cells incubated with 100 nM of estradiol and 0.07 nM of testosterone after 48 hrs by sulforhodamine B assay in presence of fetal bovine serum and NuSerum, GI50=30.1995μM | 21513275 | ||
| NCI-ADR-RES | Antiproliferative assay | 48 hrs | Antiproliferative activity against estrogen receptor-deficient human NCI-ADR-RES cells incubated with 0.003 nM of estradiol and 0.01 nM of testosterone after 48 hrs by sulforhodamine B assay in presence of 5% fetal bovine serum, GI50=32.3594μM | 21513275 | ||
| MCF12A | Antiproliferative assay | 48 hrs | Antiproliferative activity against estrogen receptor-deficient human MCF12A cells incubated with 0.003 nM of estradiol and 0.01 nM of testosterone after 48 hrs by sulforhodamine B assay in presence of 5% fetal bovine serum, GI50=32.3594μM | 21513275 | ||
| LNCAP | Antiproliferative assay | 48 hrs | Antiproliferative activity against human LNCAP cells expressing androgen receptor incubated with 0.6 nM of estradiol and 0.7 nM of testosterone after 48 hrs by sulforhodamine B assay, GI50=38.9045μM | 21513275 | ||
| PC3 | Antiproliferative assay | 48 hrs | Antiproliferative activity against androgen receptor-deficient human PC3 cells incubated with 0.6 nM of estradiol and 0.7 nM of testosterone after 48 hrs by sulforhodamine B assay, GI50=42.6579μM | 21513275 | ||
| MCF7 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human MCF7 cells expressing estrogen receptor incubated with 0.06 nM of estradiol and 0.07 nM of testosterone after 48 hrs by sulforhodamine B assay in presence of fetal bovine serum and NuSerum, GI50=45.7088μM | 21513275 | ||
| FRT | Function assay | 24 hrs | Binding affinity to CFTR F508 deletion mutant expressed in forskolin-stimulated FRT cells assessed as increase in iodine influx measured as YFP quenching rate after 24 hrs by fluorescence assay, Kd=9.4μM | 21568323 | ||
| MCF7 | Antiestrogenic assay | 1 to 20 uM | 48 hrs | Antiestrogenic activity in human ER-positive MCF7 cells assessed as inhibition of 17beta estradiol-induced secreted alkaline phosphatase activity at 1 to 20 uM after 48 hrs by phospha-light reporter chemiluminescence assay | 21800859 | |
| Jurkat T | Apoptosis assay | 36 hrs | Induction of apoptosis in human Jurkat T cells overexpressing Neo after 36 hrs by flow cytometry | 22197393 | ||
| FRT | Function assay | Potentiation activity at human CFTR delta F508 mutant-mediated iodine flux expressed in rat FRT cells coexpressing fluorescent protein YFP-H148Q/1152L by fluorescence assay, EC50=7μM | 22281185 | |||
| Human Huh7.5.1 | Antiviral assay | 72 hrs | Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay, EC50=14.4μM | 22445328 | ||
| CHO | Function assay | Ki values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells, Ki=2.96μM | 23571415 | |||
| CHO | Function assay | pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells, IC50=3.89045μM | 23571415 | |||
| CHO | Function assay | Ki values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells, Ki=5μM | 23571415 | |||
| CHO | Function assay | pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells, IC50=9.12011μM | 23571415 | |||
| HuH7 | Antiplasmodial assay | 24 hrs | Antiplasmodial activity against liver sporozoite stage of Plasmodium berghei ANKA expressing GFP infected in human HuH7 cells assessed as inhibition of parasite development after 24 hrs by qRT-PCR analysis, IC50=20μM | 24125849 | ||
| SKBR3 | Cell cycle assay | 50 to 75 uM | 36 hrs | Cell cycle arrest in human SKBR3 cells assessed as decrease in accumulation at G0/G1 phase at 50 to 75 uM after 36 hrs by propidium iodide staining-based flow cytometric analysis | 24456004 | |
| A431 | Cell cycle assay | 50 to 75 uM | 36 hrs | Cell cycle arrest in human A431 cells assessed as decrease in accumulation at G0/G1 phase at 50 to 75 uM after 36 hrs by propidium iodide staining-based flow cytometric analysis | 24456004 | |
| A431 | Cell cycle assay | 50 to 75 uM | 36 hrs | Cell cycle arrest in human A431 cells assessed as accumulation at G2/M phase at 50 to 75 uM after 36 hrs by propidium iodide staining-based flow cytometric analysis relative to control | 24456004 | |
| A431 | Apoptosis assay | 50 to 75 uM | 72 hrs | Induction of apoptosis in human A431 cells overexpressing ErbB in complete medium assessed as late apoptotic/necrotic cells at 50 to 75 uM after 72 hrs by annexin V-FITC/7-AAD staining-based flow cytometric analysis | 24456004 | |
| MCF7 | Growth inhibition assay | 0.1 to 20 uM | 4 days | Stimulation of growth in human MCF7 cells at 0.1 to 20 uM after 4 days by MTT assay | 25078314 | |
| MCF7 | Growth inhibition assay | 20 to 100 uM | 4 days | Growth inhibition in human MCF7 cells at 20 to 100 uM after 4 days by MTT assay | 25078314 | |
| RAW264.7 | Function assay | 26 uM | Inhibition of nitric oxide production in LPS/IFNgamma-stimulated mouse RAW264.7 cells assessed as nitrites level at 26 uM by Griess method (Rvb = 6.4 +/- 0.5 uM), Activity=6.1μM | 25127153 | ||
| RAW264.7 | Function assay | 6.5 uM | Inhibition of nitric oxide production in LPS/IFNgamma-stimulated mouse RAW264.7 cells assessed as nitrites level at 6.5 uM by Griess method (Rvb = 6.4 +/- 0.5 uM), Activity=6.3μM | 25127153 | ||
| RAW264.7 | Function assay | 13 uM | Inhibition of nitric oxide production in LPS/IFNgamma-stimulated mouse RAW264.7 cells assessed as nitrites level at 13 uM by Griess method (Rvb = 6.4 +/- 0.5 uM), Activity=6.3μM | 25127153 | ||
| J774A1 | Function assay | 6.5 uM | Inhibition of nitric oxide production in LPS/IFNgamma-stimulated mouse J774A1 cells assessed as nitrites level at 6.5 uM by Griess method (Rvb = 16.5 +/- 1.4 uM), Activity=13.4μM | 25127153 | ||
| J774A1 | Function assay | 13 uM | Inhibition of nitric oxide production in LPS/IFNgamma-stimulated mouse J774A1 cells assessed as nitrites level at 13 uM by Griess method (Rvb = 16.5 +/- 1.4 uM), Activity=13.8μM | 25127153 | ||
| J774A1 | Function assay | 26 uM | Inhibition of nitric oxide production in LPS/IFNgamma-stimulated mouse J774A1 cells assessed as nitrites level at 26 uM by Griess method (Rvb = 16.5 +/- 1.4 uM), Activity=14.5μM | 25127153 | ||
| HEK293 | Function assay | Inhibition of EGFR (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay, IC50=25.12μM | 25205190 | |||
| Sf9 | Function assay | Inhibition of His6-tagged human recombinant DNMT1 expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scintil, IC50=30μM | 25406944 | |||
| LNCAP | Cytotoxicity assay | 3 days | Cytotoxicity against human androgen-dependent LNCAP cells assessed as inhibition of cell viability after 3 days by WST-1 cell proliferation assay, IC50=37.4μM | 26341135 | ||
| insect cells | Function assay | 10 mins | Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells preincubated for 10 mins followed by addition of kynuramine as substrate, IC50=3.9μM | 27575476 | ||
| insect cells | Function assay | 10 mins | Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells preincubated for 10 mins followed by addition of benzylamine as substrate, IC50=4.1μM | 27575476 | ||
| insect cells | Function assay | 40 mins | Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells assessed as decrease in arbitrary light units preincubated for 40 mins followed by addition of luciferin derivative substrate measured after 2 hrs by MAO-Glow assay, IC50=6.8μM | 27575476 | ||
| insect cells | Function assay | 40 mins | Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells assessed as decrease in arbitrary light units preincubated for 40 mins followed by addition of luciferin derivative substrate measured after 2 hrs by MAO-Glow assay, IC50=9.7μM | 27575476 | ||
| RAW264.7 | Antiosteoporotic assay | 4 to 5 days | Antiosteoporotic activity in mouse RAW264.7 cells assessed as inhibition of RANKL-induced osteoclast differentiation after 4 to 5 days by TRAP assay, IC50=11.4μM | 28169537 | ||
| SK-MEL-2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=36μM | 28654265 | ||
| MML1 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MML1 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=42μM | 28654265 | ||
| MDA-MB-231 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=43μM | 28654265 | ||
| LN229 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=44μM | 28654265 | ||
| NCI-H460 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=47μM | 28654265 | ||
| T47D | Cytotoxicity assay | 48 hrs | Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=48μM | 28654265 | ||
| HepG2 | Function assay | 1 hr | Inhibition of IL-6-Induced STAT3 activation (unknown origin) expressed in human HepG2 cells expressing pSTAT3-luciferase pre-incubated for 1 hr before IL-6 stimulation for 6 hrs by luciferase reporter gene assay, IC50=24.8μM | 29140705 | ||
| UOCB1 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human UOCB1 cells after 72 hrs by CelTiter-Glo assay, EC50=35.6958μM | 29407975 | ||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | |||
| LNCAP | Antiproliferative assay | Antiproliferative activity against human LNCAP cells, IC50=10μM | 29456113 | |||
| LNCAP | Antiproliferative assay | 72 hrs | Antiproliferative activity against human LNCAP cells after 72 hrs by MTS assay, IC50=24μM | 29456113 | ||
| LNCAP | Antiproliferative assay | 72 hrs | Antiproliferative activity against human LNCAP cells after 72 hrs in presence of enzalutamide by MTS assay, IC50=31.7μM | 29456113 | ||
| LNCAP | Function assay | 2.5 uM | 24 hrs | Inhibition of HDAC6/HSP90 in human LNCAP cells assessed as downregulation of AR protein level at 2.5 uM after 24 hrs by Western blot method | 29456113 | |
| BV2 | Antiinflammatory assay | Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production, IC50=28.4μM | 29482940 | |||
| MDA-MB-231/beta41 | Estrogenic assay | 18 hrs | Estrogenic activity at ERbeta (unknown origin) expressed in human MDA-MB-231/beta41 cells after 18 hrs by renilla luciferase reporter gene assay, EC50=0.0024μM | 29641206 | ||
| Ishikawa | Estrogenic assay | 96 hrs | Estrogenic activity at ERalpha in human Ishikawa cells assessed as induction of alkaline phosphatase activity using p-nitrophenol as substrate treated for 96 hrs followed by substrate addition by spectrophotometric method, EC50=0.24μM | 29641206 | ||
| HEK293 | Function assay | 48 hrs | Agonist activity at human ER-beta transfected in HEK293 cells after 48 hrs by luciferase reporter gene assay, EC50=0.01995μM | ChEMBL | ||
| HEK293 | Function assay | 48 hrs | Agonist activity at human ER-alpha transfected in HEK293 cells after 48 hrs by luciferase reporter gene assay, EC50=0.50119μM | ChEMBL | ||
| HT-29 | Growth inhibition assay | Growth inhibition of Homo sapiens (human) HT-29 cells by MTT assay, GI=4.11μM | ChEMBL | |||
| HL60 | Growth inhibition assay | Growth inhibition of Homo sapiens (human) HL60 cells by MTT assay, GI=4.82μM | ChEMBL | |||
| SGC7901 | Growth inhibition assay | Growth inhibition of Homo sapiens (human) SGC7901 cells by MTT assay, GI=5.78μM | ChEMBL | |||
| HL60 | Function assay | Competitive inhibition of GLUT1 in human HL60 cells assessed as reduction in 2-[1,2-3H]deoxy-D-glucose uptake measured for 30 secs by double reciprocal plot analysis, Ki=7μM | ChEMBL | |||
| CHO | Function assay | Competitive inhibition of GLUT1 (unknown origin) expressed in CHO cells assessed as reduction in 2-[1,2-3H]deoxy-D-glucose uptake measured for 30 secs by double reciprocal plot analysis, Ki=7μM | ChEMBL | |||
| 3T3L1 | Function assay | Inhibition of GLUT4 in mouse 3T3L1 cells assessed as reduction in insulin-stimulated 2-deoxy-D-[14C]glucose uptake, IC50=20μM | ChEMBL | |||
| 클릭하여 더 많은 세포주 실험 데이터 보기 | ||||||
| 분자량 | 270.24 | 화학식 | C15H10O5 |
보관 (수령일로부터) | |
|---|---|---|---|---|---|
| CAS 번호 | 446-72-0 | SDF 다운로드 | 원액 보관 |
|
|
| 동의어 | NPI 031L | Smiles | C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O | ||
|
In vitro |
DMSO
: 54 mg/mL
(199.82 mM)
Ethanol : 4 mg/mL Water : Insoluble |
|
In vivo |
|||||
1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)
2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)
계산 결과:
작업 농도: mg/ml;
DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.
참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.
| Targets/IC50/Ki |
EGFR
topo II
|
|---|---|
| 시험관 내(In vitro) |
Genistein은 ATP 경쟁적 억제제입니다. 이 화합물은 분리된 효소 및 수용체 준비물과 혈소판, 림프구 및 다양한 배양 세포를 포함한 전체 세포에서 티로신 인산화를 억제합니다. 또한 배양 세포에서 EGF 자극 인산화를 억제하고 Topo II (topoisomerase II) 억제 효과도 가집니다. 이 화학물질은 배양된 A431 표피양 암종 세포에서 EGF 자극 티로신 인산화를 억제합니다. 억제는 ATP에 경쟁적이며 기질에 비경쟁적입니다. 이는 NIH-3T3 세포에서 EGF와 트롬빈에 의해 매개되는 유사분열 효과를 차단합니다. 이 화합물은 또한 GPR30 수용체에서 작용제 역할을 하며 PPARγ 및 에스트로겐 수용체와 결합합니다. 또한 PPARγ와 결합하여 Ki가 5.7 μM인 이 수용체에서 작용제 역할을 합니다. |
| 생체 내(In vivo) |
Genistein은 성체 동물에서 유방암, 전립선암 및 기타 내분비 의존성 종양에 대한 화학 예방 효과가 있습니다. 식이 내 이 화합물은 용량 의존적으로 분화가 불량한 전립선 선암종의 발생률을 감소시키고 안드로겐 수용체, 에스트로겐 수용체-알파, 표피 성장 인자 수용체 및 세포외 신호 조절 키나아제-1을 하향 조절했지만, 에스트로겐 수용체-베타 및 형질전환 성장 인자-알파 mRNA 발현은 조절하지 않았습니다. 식이 Genistein은 특정 성 스테로이드 수용체 및 성장 인자 신호 전달 경로를 조절하여 유방암 및 전립선암으로부터 보호합니다. 이 화학물질을 전립선 종양 방사선 조사와 병용하면 원발성 종양 성장을 더 크게 억제하고 대동맥 주변 림프절로의 자발적 전이를 제어하여 생쥐 생존율을 높입니다. 역설적으로, 이 화합물 단독 치료는 림프절로의 전이를 증가시킵니다. |
참조 |
|
| 방법 | 바이오마커 | 이미지 | PMID |
|---|---|---|---|
| Western blot | PPARγ / C/EBPα / αP2 p-ERK Foxo3 CIP2A / PARP / Cleaved PARP / Caspase-3 / Cleaved Caspase-3 p-AKT / AKT DNMT-1 / DNMT-3a / DNMT-3b |
|
18384126 |
| Immunofluorescence | ER-β / pS87 ER-β |
|
25931004 |
(데이터 출처 https://clinicaltrials.gov, 업데이트 날짜 2024-05-22)
| NCT 번호 | 모집 | 조건 | 스폰서/협력자 | 시작일 | 단계 |
|---|---|---|---|---|---|
| NCT05073523 | Completed | Healthy |
Chalmers University of Technology |
September 27 2021 | Not Applicable |
| NCT04650555 | Completed | Acute Radiation Syndrome |
Humanetics Corporation|United States Department of Defense|Joint Warfighter Medical Research Program |
December 8 2020 | Phase 1 |
| NCT01982578 | Completed | Alzheimer''s Disease |
Fundación para la Investigación del Hospital Clínico de Valencia|University of Valencia |
September 1 2017 | Not Applicable |
| NCT02499861 | Completed | Cancer |
St. Justine''s Hospital |
July 2015 | Phase 1|Phase 2 |
| NCT01628471 | Completed | Non Small Cell Lung Cancer |
Uman Pharma|DSM Nutritional Products Inc.|MDEIE Ministry Québec Government|INRS-Institut Armand Frappier Université du Québec |
November 2012 | Phase 1|Phase 2 |